Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$-0.15
EPS est.
$-0.33
EPS surprise
+54.95%
1-day move
+3.02%
Summit Therapeutics reported a better-than-expected EPS for Q1-2026, which contributed to a 3.02% increase in stock price. The company did not provide revenue figures or any forward guidance, leaving investors with limited insights into future performance. The positive EPS surprise may indicate improved cost management or operational efficiencies.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | $-0.21 | +54.95% |
| Revenue | N/A | $0M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing innovative medicines for serious diseases. With a market cap of $16 billion, it operates in the health care sector, which is increasingly important as demand for new therapies continues to grow.
Last quarter
In the last quarter (Q4-2025), Summit reported an EPS of $-0.14, which was better than the expected $-0.22, resulting in a positive stock reaction of 0.94%. However, revenue figures were not disclosed, leaving some uncertainty.
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+21.04%
Avg 1-day reaction
-3.44%
Analysts expect a loss of $-0.21 per share this quarter, with no revenue anticipated. The market is watching closely for any surprises in earnings or potential revenue.
Bull case
If Summit can report a smaller loss than expected or even generate some revenue, it could signal positive momentum and boost investor confidence.
Bear case
Conversely, if the company reports a larger loss or fails to provide any revenue, it may raise concerns about its financial health and future prospects.
Key metrics to watch
EPS
$-0.21Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for any signs of improvement.
Revenue
$0MEven though revenue expectations are low, any reported revenue could indicate progress in product development or market acceptance.
The print will turn on these.
Q1
Will the EPS be better than the consensus estimate of $-0.21?
A smaller loss could indicate improved operational efficiency and may positively influence investor sentiment.
Q2
Is there any revenue reported this quarter?
Any revenue, even if minimal, could signal progress in product development and market acceptance, which is crucial for future growth.
—
Est. EPS
$1.36
Est. Rev
$1.9B
Impl. Move
±7.8%
Why consensus could be wrong
The Street may be underestimating the potential for a smaller-than-expected loss this quarter, given the company's recent trend of beating EPS estimates.
Supporting evidence
Summit has consistently surprised to the upside on EPS in recent quarters, with an 88% beat rate.
Options pricing suggests a larger move than historical averages, indicating that traders expect significant news.
The lack of revenue expectations may lead to lower thresholds for positive reactions.
Key risk
If the EPS comes in better than $-0.21, it could shift sentiment significantly.
Pre-commit to what would confirm each case.
This quarter's results will help determine whether Summit is making progress in its product pipeline and financial health.
Bull confirmed if
Reporting an EPS loss of less than $-0.21 and generating any revenue would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-0.21 without any revenue would confirm the bear case.
What the market is pricing for the move.
Implied Move
±10.24%
Historical Avg
±5.4%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±10.2% while SMMT has averaged ±5.4% over the last 8 prints — setup is pricing rich.
ATM IV
1.7%
30d HV
84.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 9 of 23 (39%)
This setup has occurred 30 times across Health Care in the last 2 years. 14 of 23 (61%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.3%, with a raw directional average of +2.4% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
17.58%
of float
Insider
80.89%
of float
Holders
330
institutions
Top Holders· as of Jun 2026
Baker Bros. Advisors, LP
32,786,348 sh · $588.5M
4.11%
-9.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Summit beats expectations and raises guidance, history suggests the stock could move up by an average of 2.37% on the first day.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.
Miss
A miss on earnings could lead to a decline of about 1.43% on the first day, as seen in past performance.
The lines on the call that would change the story.
FMR, LLC
10,043,947 sh · $180.3M
1.26%
-7.5%
State Street Corporation
9,536,796 sh · $171.2M
1.20%
35.7%
Blackrock Inc.
9,529,041 sh · $171.0M
1.19%
-1.3%
Vanguard Capital Management LLC
5,734,484 sh · $102.9M
0.72%
0.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.